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TREM-1 links dyslipidemia to inﬂammation
and lipid deposition in atherosclerosis
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Triggering receptor expressed on myeloid cells-1 (TREM-1) is a potent ampliﬁer of
pro-inﬂammatory innate immune responses, but its signiﬁcance in non-infectious diseases
remains unclear. Here, we demonstrate that TREM-1 promotes cardiovascular disease by
exacerbating atherosclerosis. TREM-1 is expressed in advanced human atheromas and is
highly upregulated under dyslipidemic conditions on circulating and on lesion-inﬁltrating
myeloid cells in the Apoe / mouse model. TREM-1 strongly contributes to high-fat,
high-cholesterol diet (HFCD)-induced monocytosis and synergizes with HFCD
serum-derived factors to promote pro-inﬂammatory cytokine responses and foam cell
formation of human monocyte/macrophages. Trem1 /Apoe / mice exhibit substantially
attenuated diet-induced atherogenesis. In particular, our results identify skewed monocyte
differentiation and enhanced lipid accumulation as novel mechanisms through which TREM-1
can promote atherosclerosis. Collectively, our ﬁndings illustrate that dyslipidemia induces
TREM-1 surface expression on myeloid cells and subsequently synergizes with TREM-1 to
enhance monopoiesis, pro-atherogenic cytokine production and foam cell formation.
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C
ardiovascular disease represents the leading cause of
mortality in industrialized nations. The main underlying
pathological process is atherosclerosis, which is increas-
ingly recognized as a complex chronic inﬂammatory disease of
the arteries that is critically driven by cells and mediators of the
innate immune system1. Murine models of atherosclerosis have
ﬁrmly established the causal link between hypercholesterolemia,
monocytosis, lesional macrophages and atherosclerotic plaque
severity2,3. Accordingly, a hypercholesterolemic environment
directly acts on bone marrow (BM) haematopoietic stem and
progenitor cells to trigger myelopoiesis4. Circulating monocytes
are recruited to arterial vessels where the endothelium has been
activated by the retention and oxidation of low-density
lipoproteins (LDL)5,6. Following their transmigration to the
intima, monocytes differentiate to macrophages and upregulate
expression of scavenger receptors. Through the ingestion of
oxidized LDL (oxLDL) and ensuing cholesterol accumulation,
these macrophages turn into pro-inﬂammatory lipid-laden foam
cells which critically contribute to lesion growth6,7. While it is
accepted that mainly the pro-inﬂammatory Ly6Chi monocytes
give rise to foam cells2,3,8,9, the reported presence of distinct
lesional macrophage subsets with discrete functional proﬁles
remains difﬁcult to apprehend10,11, in particular, as arterial
macrophages are of diverse developmental origins12 and local
proliferation also appears to contribute to the lesional
macrophage pool13.
The signiﬁcance of innate immune activation in atherosclerosis
and the largely non-infectious aetiology of the disease raise
intriguing questions regarding the factors and receptors that can
mediate the stimulation of primary monocytes, promote their
differentiation into macrophages and sustain the chronic
activation of lesional macrophages. Mice lacking Toll-like
receptors 4 (TLR4) or myeloid differentiation primary response
gene 88 (MyD88) exhibit substantially reduced plaque size14,15,
however, raising the atherosclerosis-susceptible Apoe / strain
on a germ-free background does not confer protection16.
An increasing wealth of data indeed suggests that endogenous
factors representing danger-associated molecular patterns
(DAMP) may play a fundamental role in the triggering
of TLR, nucleotide-binding and oligomerization domain
(NOD)-like receptor (NLR) family members and other
pattern recognition receptors (PRR) in the context of the sterile
inﬂammatory process in atherosclerosis1. Heat-shock protein 60,
saturated fatty acids and modiﬁed LDL have been documented as
ligands for TLR4 (refs 1,17). Experimental blockade of the DAMP
molecule high-mobility group box protein-1 (HMGB1), which is
released by necrotic cells and activated macrophages and is
overexpressed in atherosclerotic lesions18, reduces development
of atherosclerosis19. Recent studies have further identiﬁed
cholesterol crystal-mediated activation of the NOD-like receptor
protein 3 (NLRP3) inﬂammasome20,21 and fatty acid-induced
mitochondrial uncoupling22 as novel links between metabolic
stress, IL-1-driven innate inﬂammation and atherogenesis.
Importantly, emerging evidence strongly suggests that PRR act
together or with other cell surface receptors to initiate and
amplify signalling in atherosclerosis as illustrated by the
non-redundant role of the oxLDL-binding type B scavenger
receptor CD36 in coordinating NLRP3 activation and TLR4/6
assembly23,24.
Triggering receptor expressed on myeloid cells-1 (TREM-1)
potently ampliﬁes oxidative burst and pro-inﬂammatory cytokine
secretion when signalling in concert with other PRR25,26. The role
of TREM-1 has mostly been acknowledged from acute infection
models where blockade of TREM-1 conferred signiﬁcant
protection27. However, data generated by us and others
strongly suggest—in line with the identiﬁcation of HMGB1 and
multimerized peptidoglycan recognition protein-1 (PGLYRP1) as
potential non-bacterial ligands28–30—that TREM-1 may also
substantially contribute to chronic and non-infectious
inﬂammatory conditions29,31–40. On the basis of the prominent
expression of TREM-1 by neutrophils and monocytes and its
synergistic action with both TLRs and PRRs of the NACHT-LRR
class25,26, we hypothesized that TREM-1 represents a central
player for innate immune activation in atherosclerosis. Here, we
demonstrate that TREM-1 indeed aggravates diet-induced
atherogenesis. Mechanistically, TREM-1-mediated signalling
exacerbates monocytosis in vivo by skewing myeloid
differentiation towards increased monocyte output. Moreover,
TREM-1 stimulation potently impacts on the expression of CD36
as well as other genes involved in lipid metabolism and augments
the pro-inﬂammatory cytokine responses and foam cell formation
of human monocytes/macrophages in vitro. Our ﬁndings
establish a distinct role for TREM-1 in a chronic inﬂammatory
disorder of non-infectious origin and reveal two so far
unappreciated effects of TREM-1 on myelopoiesis and cellular
cholesterol metabolism.
Results
TREM-1 aggravates atherosclerosis. We assessed the
potential role of TREM-1 in atherogenesis using the Trem1 /
mouse strain that was recently generated and characterized by
our laboratory31. Trem1 / mice were backcrossed onto the
atherosclerosis-susceptible Apoe / background and 6–8-week-
old female Trem1 / Apoe / and Trem1þ /þ Apoe /
mice were concurrently placed on a high-fat, high-cholesterol-
containing diet (HFCD). At 16 weeks post HFCD feeding,
Trem1 / Apoe / mice exhibited a 40% reduction in the
overall extent of atherosclerosis in the aorta (Fig. 1a,b). The
decreased atherosclerotic surface area in Trem1 / Apoe /
mice was due to a substantially smaller average lesion size rather
than being associated with reduced numbers of individually
enumerable lesions (Fig. 1c,d). While the effect of the TREM-1
deﬁciency was clearly apparent throughout the aorta, this
difference was not reﬂected by the cross-sectional lesion area at
the aortic root (Fig. 1e,f). Atherosclerotic lesions usually develop
ﬁrst at this anatomical site and had, at 16 weeks post HFCD,
already progressed to very advanced plaques, thus very likely
masking the effect of TREM-1 deﬁciency on atherogenesis.
The pro-atherogenic impact of TREM-1 was not mediated
by effects on lipid metabolism, since HFCD-fed Trem1 /
Apoe / and Trem1þ /þ Apoe / mice exhibited similar total
cholesterol, HDL-cholesterol and LDL-cholesterol levels (Fig. 1g).
Moreover, HFCD-fed Trem1 / Apoe / and Trem1þ /þ
Apoe / mice showed comparable fasting blood glucose levels
and similar glucose clearance upon oral glucose challenge, which
indicated equal insulin sensitivity in both groups of mice
(Supplementary Fig. 1e–g). Taken together, these ﬁndings
suggested a major impact of TREM-1 on atherosclerotic lesion
progression but ruled out systemic effects on lipid or glucose
metabolism as an underlying mechanism.
TREM-1 exacerbates dyslipidemia dependent monocytosis. In
experimental models of diet-induced atherogenesis the severity
of atherosclerosis closely correlates with increased numbers of
circulating monocytes and neutrophils2,41. We therefore
analysed the absolute numbers of peripheral blood myeloid cell
subsets after 4 and 16 weeks of HFCD feeding (Fig. 2a
and Supplementary Fig. 2a). HFCD-feeding induced a time-
dependent increase in circulating Ly6Chi monocytes in both
groups of mice (Fig. 2a). However, this HFCD-induced
monocytosis was drastically reduced in mice lacking TREM-1
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(Fig. 2a). HFCD feeding also resulted in a marked neutrophilia
that, conversely, appeared to be more pronounced in Trem1 /
Apoe / mice (Fig. 2a). To investigate the underlying
mechanisms behind the aggravated monocytosis in Trem1þ /þ
Apoe / mice, we examined the BM of 16-week chow diet or
HFCD-fed mice (Fig. 2b–d and Supplementary Fig. 2b). Under
chow-diet feeding, common myeloid progenitors (CMP)
were phenotypically increased while granulocyte/macrophage
progenitors (GMP) were signiﬁcantly reduced in frequencies in
Trem1 / Apoe / mice (Fig. 2b). In contrast, frequencies of
both CMPs and GMPs were decreased in Trem1 / Apoe /
mice under HFCD (Fig. 2b). Frequencies of lineage-negative
(lin ) cKithi Sca1þ stem/progenitor cells (LSK) were
comparable between the two groups independently of the diet
(Fig. 2b). To determine whether the enforced monocytosis in
Trem1þ /þ Apoe / mice was related to functional alterations
in haematopoietic stem/progenitor cells, we determined myeloid
BM colony-forming unit (CFU) capacity under chow diet and
HFCD feeding. Both groups of mice had comparable CFUs
irrespective of the diet (Fig. 2c). Surprisingly, however, HFCD-fed
Trem1þ /þ Apoe / mice formed more monocyte colonies (M)
at the expense of granulocyte colonies (G) (Fig. 2d,e). In line with
this ﬁnding, GMP from HFCD-fed Trem1þ /þ Apoe / mice
exhibited increased mRNA for Irf8, which is a key regulator of
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Figure 1 | TREM-1 promotes atherogenesis in absence of an altered lipid metabolism. (a–d) Extent of atherosclerosis in female Trem1þ /þ Apoe /
(n¼ 13) and Trem1 / Apoe / mice (n¼ 12) at 16 weeks post HFCD feeding as assessed by computational analysis of Oil-red O (ORO) stained aortas.
(a) Selected examples of en face preparations of the aortas; for each group of mice, an aorta with a representative extent of atherosclerosis is shown. Scale
bars, 10mm. (b) Overall extent of atherosclerosis (aortic lesion surface area expressed as % of total aortic surface). (c) Mean individual lesion size per
individual mouse and aorta. (d) Number of enumerable lesions per aorta. (b–d) Circles show individual data for mice from three pooled independent
experiments, lines indicate mean values per group of mice. (e,f) Extent of atherosclerotic lesions in the aortic root at 16 weeks post HFCD feeding.
(e) Representative examples of ORO-stained sections of the aortic root. Scale bars, 500mm. (f) The lesion area was calculated from 10 sequential
ORO-stained sections for each Trem1þ /þ Apoe / (n¼ 11) and Trem1 / Apoe / (n¼ 12) mouse. Circles show data for individual mice. (g) Fasting
serum concentrations of total cholesterol, HDL-cholesterol and LDL cholesterol of Trem1þ /þ Apoe / (n¼ 13) and Trem1 / Apoe / (n¼ 12) mice at
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monocytic over granulocytic lineage differentiation (Fig. 2f)42.
GMP, but not CMP or LSK cells, also expressed distinct levels of
surface TREM-1 (Supplementary Fig. 2c)31. TREM-1 expression
on GMP was not further increased by HFCD compared with
chow diet feeding (Supplementary Fig. 2c); moreover, activation
of sorted GMP by plate-bound anti-TREM-1 in presence or
absence of HFCD serum did not augment monocyte
differentiation in vitro (Supplementary Fig. 2d,e). These results
indicated that the effect of TREM-1 on skewed monocyte
differentiation was potentially indirect and/or upstream of GMP.
Considering the synergistic impact of dyslipidemia and
TREM-1 on the peripheral immune compartment, we in turn
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assessed the potential impact of HFCD feeding on TREM-1
surface expression by peripheral blood myeloid cell subsets.
Concordant with previous ﬁndings31,43, TREM-1 was highly
expressed on neutrophils and to a lower degree on Ly6Clo
monocytes in chow-fed mice while no surface expression was
detected on Ly6Chi monocytes (Fig. 2g). Intriguingly, HFCD
feeding markedly upregulated TREM-1 expression on all myeloid
subsets. The increase was most prominent for neutrophils and
Ly6Clo monocytes, but was also evident for Ly6Chi monocytes
(Fig. 2g,h). The modulated expression of surface TREM-1 was
paralleled by an increase in serum sTREM-1 that was apparent
already at 4 weeks post HFCD (Fig. 2i).
Taken together, these results suggested that dyslipidemia
distinctly increases expression of TREM-1 on all circulating
myeloid cell subsets and that TREM-1-mediated signalling in
turn provokes skewed monocyte differentiation in the BM,
resulting in exacerbated monocytosis and atherogenesis.
TREM-1 augments aortic macrophage accumulation. While our
data so far suggested a contribution of TREM-1 to the HFCD-
induced monocytosis, we also sought to investigate a potential
contribution of TREM-1-expressing cells within the progressing
atherosclerotic plaque. Trem1 mRNA was barely detectable
in the aortic arches of young (before HFCD) or of
16-week chow diet-fed Trem1þ /þ Apoe / (Fig. 3a). In con-
trast, 16-week HFCD feeding resulted in a markedly upregulated
expression of TREM-1 mRNA (Fig. 3a and Supplementary
Fig. 3a). The increased abundance of Trem1 transcripts was
paralleled by a substantial appearance of Cd68 but not Ly6g
expression (Fig. 3a), illustrating that lesion formation and
vascular monocyte-macrophage accumulation rather than
neutrophil inﬁltration correlated with Trem1 expression. In line
with this, also expression of Trem2 but not Treml1 or Treml4
was higher in the aortic arch of 16-week HFCD-fed
Trem1þ /þ Apoe / mice compared to Trem1 / Apoe /
mice (Supplementary Fig. 3b).
The parallel increase in Trem1 and Cd68 transcripts at
16-weeks post HFCD indicated that not only the TREM-1-driven
peripheral monocytosis but also local TREM-1-mediated
activation of monocyte/macrophages could contribute to athero-
sclerotic lesion development. To further elucidate potential
mechanisms underlying TREM-1-stimulated lesion progression,
we subjected aortic tissues to a Nanostring-based gene expression
proﬁling, using the nCounter Mouse Immunology panel
supplemented with 30 genes of interest (Supplementary
Table 1). Since the extremely low number of macrophages that
were retrieved from digested aortas precluded gene expression
analysis in isolated cells, we directed our analysis to the aortic
arch where the least differences in total lesion size were observed
between the two groups of mice at 16-weeks post HFCD feeding.
Principal component analysis of the NanoString data indicated
that the largest possible variance was induced by HFCD
compared to chow diet feeding (Fig. 3b). However, among
HFCD-fed mice, variances in gene expression were nonetheless
evident between the Trem1þ /þ Apoe / or Trem1 /
Apoe / group (Fig. 3b,c and Supplementary Table 2).
As anticipated from Fig. 2a, the aggravated monocytosis in
Trem1þ /þ Apoe / mice primarily translated into increased
aortic expression of multiple monocyte/macrophage-related
markers (Fig. 3c and Supplementary Fig. 3c). Accordingly, also
the expression of several pro-inﬂammatory cytokines, oxidases
and genes involved in foam cell formation was augmented
(Fig. 3c and Supplementary Fig. 3c). Normalization of these
differentially expressed genes to monocyte/macrophage-related
markers did not demonstrate signiﬁcant differences between the
two groups of mice (Supplementary Fig. 4). Hence, the distinct
transcriptional proﬁle of whole aortic tissue from HFCD-fed
Trem1þ /þ Apoe / mice was mainly reﬂective of increased
monocyte/macrophage accumulation rather than altered gene
expression patterns on a per cell level. While these results did not
indicate an unequivocal mechanism for a local contribution
of TREM-1 to atherosclerotic lesion progression, the data
ﬁrmly established increased monocyte/macrophage inﬁltration
as a major pro-atherogenic consequence of TREM-1-mediated
signalling in HFCD-fed Trem1þ /þ Apoe / mice.
TREM-1 affects the composition of aortic myeloid cell subsets.
Enhanced expression of Trem1 at arterial sites was related to
increased monocyte/macrophage accumulation (Fig. 3a,c and
Supplementary Fig. 3). However, lesional macrophages are likely
composed of heterogeneous populations comprising differ-
entiated macrophage foam cells but also recently recruited
monocytes, which could differ in their expression of TREM-1. To
gain insight into potential roles of TREM-1-expressing myeloid
cell subsets at arterial sites, we aimed to identify the major
TREM-1-expressing cell subset in atherosclerotic lesions. In
addition, we sought to determine whether TREM-1 could con-
tribute to lesion progression by inﬂuencing the composition of
plaque-inﬁltrating monocyte/macrophage populations. We chose
a ﬂow cytometry approach to analyse enzymatically digested
aortas derived from Trem1þ /þApoe / and Trem1 /
Apoe / mice at 16 weeks post HFCD feeding. Among single,
live- non-autoﬂuorescent cells we pre-gated on CD45þ CD11bþ
cells and subsequently excluded MHCIIþ CD11cþ cells which
represented dendritic cells12,44 (Supplementary Fig. 5a). Within
the remaining CD11bþ population we distinguished ﬁve myeloid
Figure 2 | TREM-1 drives skewed monocyte differentiation and HFCD-dependent monocytosis. (a) Absolute numbers of peripheral blood myeloid cell
subsets before HFCD feeding (week 0; n¼4), after 4 weeks of HFCD-feeding (n¼4–5), after 16 weeks of HFCD-feeding (n¼ 13–15) and after 16 weeks of
chow-feeding (n¼9–13) as determined by ﬂow cytometry. Circles represent mean valuesþ s.d. for each group. Data are pooled from three independent
experiments for the 16-week time-point and from one experiment for the 0 and 4 week analyses. (b) Relative frequencies of LSK cells (Sca1þ cKithi),
CMP (Sca1 cKithi FcgRlo CD34þ ) and GMP (Sca1 cKithi FcgRþ CD34þ ) cells among lineage (lin ; Ter119 , CD3e , Gr1 and B220 ) and
CD127 BM cells isolated from 16-week-HFCD-fed or chow-fed mice. Bars show mean valuesþ s.d. of n¼ 6-9 HFCD-fed mice (two independent
experiments) and n¼4–5 chow-fed controls. (c) Myeloid colony-forming units per well of 5 103 plated lin BM cells and (d) relative frequencies of
colony subtypes (M: monocyte colonies; G: granulocyte colonies; GM: mixed monocyte/granulocyte colonies). Data show mean valuesþ s.d. of n¼ 6–9
HFCD-fed mice (from two independent experiments) and from n¼4–5 chow-fed mice per group. (e) Representative examples of CFU-G, CFU-M and
CFU-GM. (f) mRNA expression of Irf8 and Cebpe in GMP isolated from 16-week-HFCD-fed mice. (g) Representative histograms for TREM-1 surface
expression (lines) versus isotype control staining (ﬁlled) on peripheral blood neutrophils, Ly6Chi and Ly6Clo monocytes from Trem1þ /þ Apoe / mice 16
weeks post chow or HFCD feeding. (h) Median ﬂuorescence intensity (MFI) of TREM-1 surface expression (with subtracted MFI values of matched isotype
control-stained cells) on peripheral blood myeloid cell subsets at the indicated time points post HFCD feeding in Trem1þ /þ Apoe / (black symbols) and
Trem1 / Apoe / (open symbols) mice. Symbols indicate meanþ s.d. of n¼ 5 mice and data are representative of three independent experiments for
Trem1þ /þ Apoe / mice. (i) serum soluble TREM-1 was determined by ELISA. *Po0.05, **Po0.01, ***Po0.001 as determined by the two-way ANOVA
test (two-tailed t-test for f). Statistically not signiﬁcant differences with P40.05 are not indicated.
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cell subsets based on their expression of Ly6C and MHC
class II: 1. Neutrophils (Ly6Cint, MHCII ), which were also
Ly6Gþ (Supplementary Fig. 5b), 2. Ly6Chi monocytes (Ly6Chi,
MHCII ) 3. Ly6Cint macrophages (Ly6Cint MHCIIþ )
4. MHCIIþ macrophages (Ly6C MHCIIþ ) and 5. MHCII
macrophages (Ly6C , MHCII ) (Fig. 4a,b). The identity of
macrophages was conﬁrmed by staining for CD64 (or F4/80 in
some experiments), which was largely absent on neutrophils and
expressed at higher levels in macrophages as compared to Ly6Chi
monocytes (Fig. 4b and Supplementary Fig. 5c). Importantly, the
segregation of myeloid subsets according to their Ly6C and MHC
class II expression was adapted from the monocyte waterfall
concept of macrophage differentiation45,46, which also considers
newly recruited Ly6Chi monocytes and Ly6Cint macrophage
differentiation stages. In contrast, a general pre-gating of F4/80þ
cells a priori excludes these subsets since Ly6Chi monocytes and
Ly6Cint cells unlike MHCIIþ and MHCII macrophages are
F4/80lo/ (Supplementary Fig. 5c)12. As expected, TREM-1 was
expressed on aortic neutrophils, albeit at substantially lower levels
compared with peripheral blood neutrophils (Figs 2g and 4c).
This likely related to the enzymatic digestion protocol of aortas.
Strikingly, however, surface TREM-1 expression was also
clearly detectable on Ly6Cint MHCIIþ cells as well as on
Ly6C MHCII lesional macrophages, whereas Ly6C
MHCIIþ macrophages did not appear to express substantial
levels of TREM-1 (Fig. 4c,d).
We next compared the relative abundance of individual
myeloid cell subsets in aortic plaques of HFCD-fed Trem1þ /þ
Apoe / versus Trem1 / Apoe / mice. As anticipated
from their reduced aortic lesion size and lower expression of
macrophage-associated genes (Figs 1a–c and 3c), aortic plaques of
Trem1 / Apoe / mice contained signiﬁcantly less CD11bþ
CD11c cells (Fig. 4e). This difference appeared to be mainly due
to a signiﬁcant reduction in the percentage of Ly6C MHC II
macrophages in lesions of Trem1 / Apoe / mice (Fig. 4e).
In contrast, deﬁciency in TREM-1 did not alter the relative
abundance of inﬁltrating neutrophils and Ly6Chi monocytes
(Fig. 4e). Taken together, these results indicated that TREM-1
is expressed by aortic wall-inﬁltrating neutrophils, Ly6Cint
MHCIIþ as well as Ly6C MHCII macrophages and
that the cellular composition in Trem1þ /þ Apoe / versus
Trem1 / Apoe / mice mostly differed in the relative
abundance of aortic Ly6C MHCII macrophages.
TREM-1 and dyslipidemic factors interact reciprocally. In
aortic lesions of Trem1þ /þ Apoe / mice, highest MFI values
for surface TREM-1 were found on neutrophils, followed by
Ly6Cint MHCIIþ cells (Fig. 4c,d), which we regarded as mono-
cytes in the process of differentiating to mature macrophages
based on the sequential monocyte waterfall concept of intestinal
macrophage differentiation45,46. Indeed, in the inﬂamed colon
highest TREM-1 expression can be detected on Ly6Chi effector
monocytes followed by their Ly6Cint descendants47. Since
peripheral blood Ly6Chi monocytes have been established as
precursors for lesional macrophages2,3,8,9, yet in the mouse even
under HFCD feeding express little surface TREM-1 (Fig. 2g),
we considered the possibility that TREM-1 is upregulated upon
transendothelial migration of Ly6Chi monocytes to the
subendothelial space. The uptake of oxLDL by inﬁltrating
monocytes represents a key factor in driving macrophage foam
cell differentiation and atherogenesis48,49. Indeed, exposure to
puriﬁed endotoxin-free oxLDL, but also to heat-inactivated
dyslipidemic serum derived from HFCD-fed mice (HFCD
serum), which contains minimally modiﬁed LDL circulating
in vivo, signiﬁcantly upregulated the expression of surface
TREM-1 on human primary monocytes (Fig. 5a,b). Moreover,
mean TREM-1 MFI values for oxLDL-stimulated cells
even exceeded those observed for cells stimulated with
lipopolysaccharide (LPS) (Fig. 5b). Considering that oxLDL
represented a potential non-microbial factor capable of
upregulating TREM-1 (ref. 50,51), we next addressed whether
oxLDL and HFCD serum-derived factors could synergize
with TREM-1-mediated signals to amplify production of
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Figure 3 | Trem1 is expressed in situ and associates with increased
macrophage accumulation. (a) Trem1, Cd68 and Ly6g mRNA expression
in the aortic arch of Trem1þ /þ Apoe / mice before the start of diet
(before HFCD) and at 16 weeks post chow or HFCD feeding was
determined by qRT-PCR and normalized to the expression of Gapdh.
***Po0.001, ****Po0.0001. (b,c) RNA isolated from the aortic arch of
Trem1þ /þ Apoe / and Trem1 / Apoe / mice before HFCD (n¼ 3
per group) or at 16 weeks post chow (n¼ 3 per group) or post HFCD
feeding (n¼ 5 and 7) was subjected to Nanostring nCounter-based
quantiﬁcation of gene expression. (b) PCA analysis. Each symbol
represents an individual mouse. (c) Heat-maps of selected gene groups.
Mean log fold changes in gene expression in the aortic arch of 16-week
HFCD-fed Trem1þ /þ Apoe / (n¼ 5) over Trem1 / Apoe / (n¼ 7)
mice are shown. PCA, principle component analysis.
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pro-atherogenic cytokines, analogous to the well-established
synergistic effects of TREM-1 with LPS27. Incubation of
monocytes with oxLDL or HFCD serum alone did not induce
substantial secretion of IL-1a, IL-1b or TNFa, whereas anti-
TREM-1 stimulation in the absence of other factors distinctly
increased the production of TNFa but not of IL-1 cytokines
(Fig. 5c). As anticipated, TREM-1 stimulation synergized with
LPS for increased cytokine production. Intriguingly, exposure to
the HFCD serum strongly augmented the TREM-1-induced
secretion of IL-1a, IL-1b or TNFa while no such effect was
observed for oxLDL stimulation (Fig. 5c). This suggested that the
minimally modiﬁed LDL present in the dyslipidemic HFCD
serum rather than in vitro generated, extensively oxidized LDL
may substitute for LPS to synergize with TREM-1 stimulation
for increased pro-inﬂammatory cytokine production from
monocyte/macrophages.
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marker CD64 (line) on the indicated cell subsets (ﬁlled histograms: matched isotype control-stained cells) (Trem1þ /þ Apoe / ). (c) Representative
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two-tailed t-test. Statistically not signiﬁcant differences with P40.05 are not indicated.
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TREM-1 enhances foam cell formation in vitro. IL-1 family
cytokines have been ascribed a central role in atherogenesis52,
however, neither Il1a nor I11b were among the 111 signiﬁcantly
TREM-1-regulated genes identiﬁed in the Nanostring analysis
(Supplementary Table 2). We therefore considered additional
mechanisms that could account for a local TREM-1-mediated
lesion progression and evaluated the possibility that TREM-1-
mediated signals directly contribute to foam cell differentiation.
Because of the difﬁculty in obtaining sufﬁcient TREM-1-
expressing primary murine monocytes and the absence of
TREM-1 on peritoneal and BM-derived murine macrophages,
we used the human myelomonocytic cell line U937 that was
stably transduced with TREM-1 and DAP12 (referred to as
U937-TD) by Tessarz et al.53. Incubation of U937-TD in the
presence of murine HFCD serum and an isotype control antibody
for 48 h resulted in detectable but rather inefﬁcient foam cell
formation as assessed by Oil Red O staining (Fig. 6a,b).
In contrast, stimulation of U937-TD cells with an agonistic
anti-TREM-1 antibody lead to a signiﬁcant increase of cells
exhibiting the characteristic lipid droplets (Fig. 6a,b). The effect
was speciﬁc to TREM-1-mediated signalling as incubation of
U937-TD cells with LPS did not substantially enhance foam cell
formation (Fig. 6a,b). Foam cell formation is primarily mediated
through uptake of modiﬁed LDL through speciﬁc receptors49.
Crosslinking of TREM-1 on U937-TD in fact potently
upregulated expression of CD36 irrespective of the absence or
presence of 5% HFCD serum in the medium (Fig. 6c,d). We next
reverted to the use of primary human CD14hi monocytes as more
representative precursors for foam cells. Although the foam cell
formation capacity of in vitro cultured primary monocytes was
generally less efﬁcient, stimulation with anti-TREM-1, but not
LPS, clearly augmented the lipid droplet content (Fig. 6e,f).
Strikingly, TREM-1-mediated activation of human primary
monocytes not only increased mRNA expression of CD36 but
also of other receptors implicated in lipid uptake such as MSR1
and LDLR (Fig. 6g). Moreover, TREM-1-activated monocytes
showed reduced expression of the cholesterol efﬂux-related genes
ABCA1 and ABCG1 and altered mRNA expression of several
intracellular cholesterol transport proteins such as NPC1, NPC2
and STARD4 (Fig. 6g), the latter likely reﬂecting a compensatory
response to the increased intracellular lipid content.
Together, these results identiﬁed a so far unappreciated direct
and potent impact of TREM-1 on foam cell formation in vitro
which not only related to increased expression of speciﬁc
scavenger receptors but was generally associated with an altered
expression of genes involved in oxLDL uptake and cellular
cholesterol metabolism.
TREM1 is expressed in established human atheromas. Our data
so far demonstrated that TREM-1 promotes atherosclerotic lesion
progression in an experimental atherosclerosis model in vivo by
aggravating monocytosis and monocyte/macrophage inﬁltration
of aortas. However, the in situ expression of TREM-1 in aortic
lesions as well as the potent impact of TREM-1 on foam cell
generation in vitro suggested that TREM-1-mediated effects
indeed contribute to lesion growth locally. Since in a Russian
population-based cohort certain polymorphisms in the TREM1
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Figure 5 | TREM-1 synergizes with dyslipidemic factors for pro-inﬂammatory cytokine secretion. (a–c) Human CD14hi monocytes were
FACS-puriﬁed from buffy coats obtained from different blood donors. (a) Representative histograms for TREM-1 surface expression (lines; ﬁlled histograms
represent isotype control stained cells) on human peripheral blood CD14hi monocytes after 20 h of stimulation with the indicated stimuli. (b) MFI values for
TREM-1 surface expression after subtraction of MFI values for matched isotype control-stained cells. Bars show mean values of seven independent
experiments with error bars indicating the s.d. (c) Production of IL-1a, IL-1b and TNFa by CD14hi monocytes after 20 h of culture with the indicated factors.
Symbols show individual values of 6–7 independent experiments and different blood donors. *Po0.05, **Po0.01, ****Po0.0001 as determined by the
one-way (b) or two-way (c) ANOVA test. Statistically not signiﬁcant differences with P40.05 are not indicated.
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gene associated with a reduced risk for coronary artery disease54,
we assessed the potential expression of TREM-1 in human
atheromas. To this end, we performed quantitative real-time PCR
(qRT-PCR) analyses on RNA isolated from human formalin-ﬁxed
parafﬁn-embedded (FFPE) aortic tissue specimen displaying
either only minor alterations or severe atherosclerosis (Fig. 7a).
Similar to our ﬁndings in control or chow-fed versus HFCD-fed
Trem1þ /þ Apoe / mice (Fig. 3a), TREM1 mRNA was barely
expressed in human aortic tissues with minor histopathological
alterations (Fig. 7b). In contrast, mRNA levels for TREM-1 and
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CD68 were signiﬁcantly upregulated in advanced atheromas,
while expression of mRNA for the granulocyte marker CD15 was
not substantially increased (Fig. 7b). Hence, analogous to what we
observed in murine atherosclerotic lesions, lesional macrophages
appeared to represent a major population of TREM-1-expressing
cells also in human atheromas.
Collectively, these results from human atherosclerosis patients
and our ﬁndings from an experimental model of atherogenesis,
where deﬁciency in TREM-1 conferred signiﬁcant protection,
establish a major pathogenic role for TREM-1 in atherosclerosis.
We show that factors contained in dyslipidemic serum are
sufﬁcient to modulate expression of TREM-1 and that TREM-1 in
turn can synergize with dyslipidemia for augmented inﬂamma-
tion and foam cell formation. Based on the distinct impact of
TREM-1 on hypercholesterolemia-induced monopoiesis and its
highly upregulated expression within aortic lesions, we propose
TREM-1 as an attractive myeloid cell-speciﬁc target for
attenuating the chronic inﬂammatory process in atherosclerosis.
Discussion
The innate immune response-amplifying receptor TREM-1 was
initially recognized for its central involvement in acute microbial
driven diseases. However, emerging evidence also strongly
implicates a role for TREM-1 in non-infectious inﬂammatory
disorders, including, rheumatoid arthritis32, psoriasis33, acute
pancreatitis34, obstructive nephropathy35 and pulmonary
disease36, hepatocellular carcinoma29, lung55 and colorectal
cancer37, as well as cardiac allograft rejection38 and myocardial
infarction39.
Here, we provide evidence that TREM-1 is expressed in
murine and human atherosclerotic lesions in situ and that
TREM-1 potently exacerbated diet-induced atherogenesis. The
pro-atherogenic impact of TREM-1 was not related to effects on
systemic lipid or glucose metabolism. In contrast, our study
identiﬁes two previously unanticipated roles of TREM-1 in
regulating myelopoiesis and cellular cholesterol metabolism.
In particular, TREM-1 aggravated the dyslipidemia-induced
peripheral blood monocytosis by promoting skewed monocyte
differentiation from BM haematopoietic stem and progenitor
cells. Numerous studies have established the link between
gradually developing monocytosis and time-dependent lesion
progression in atherosclerosis. The effects of TREM-1 on the
peripheral monocyte pool only became signiﬁcant upon pro-
longed HFCD feeding. In line with this observation, we did not
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Figure 7 | TREM1 is expressed in human atheromas. (a) Representative hematoxylin and eosin stainings of sections from human aortas with either minor
alterations (left) (n¼ 10) or severe atherosclerosis (right) (n¼ 11). Scale bars, 200mm. (b) RNA was isolated from tissue rolls derived from FFPE human
aortic specimens with either only minor alterations (diamonds) or severe atherosclerosis (squares). Expression of the indicated genes was assessed by
qRT-PCR. Symbols represent values for individual patients, lines indicate mean expression. **Po0.01 as determined by the two-tailed t-test.
Figure 6 | TREM-1 promotes foam cell formation of human monocytes in vitro. (a,b) TREM-1 and DAP12-expressing U937-TD cells were incubated
for 48 h in vitro in the presence of 5% serum from HFCD-fed mice and the indicated stimuli (plate-bound anti-TREM-1, or isotype control antibody
þ / 30 ngml 1 LPS). (a) Representative photomicrograph of ORO and DAPI-stained U937-TD cells. Scale bars indicate 100mm. (b) Quantiﬁcation of
foam cell formation. The ratio of DAPI positive pixels versus ORO positive pixels was calculated using Image J software. Bars represent mean valuesþ s.d.
from 10 independent experiments. (c,d) U937-TD cells were incubated for 48 h with the indicated stimuli in the presence or absence of 5% HFCD serum.
CD36 surface expression was determined by ﬂow cytometry. (c) Representative histogram overlays showing CD36 surface expression (ﬁlled histograms
represent isotype control-stained cells) (d) MFI values for CD36 surface expression. Bars show mean valuesþ s.d. from three independent experiments.
(e–g) CD14hi monocytes were ﬂow-sorted from human blood donors. (e,f) Foam cell formation capacity of human CD14hi monocytes was determined as
described for U937-TD cells. (e) Scale bars, 100mm. (f) Bars show mean valuesþ s.d. from three independent experiments with different blood donors.
(g) After 20 h of culture with the indicated stimuli, CD14hi monocytes were harvested for qRT-PCR-based analysis of genes involved in cholesterol
metabolism. Symbols show expression levels for n¼ 7 independent experiments with different blood donors. *Po0.05, **Po0.01 as determined by the
one-way ANOVA test (b–f) and the paired t-test (g). Statistically not signiﬁcant differences with P40.05 are not indicated.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13151
10 NATURE COMMUNICATIONS | 7:13151 | DOI: 10.1038/ncomms13151 | www.nature.com/naturecommunications
note differences in the extent of early atherosclerotic lesions in
Trem1þ /þ Apoe / versus Trem1 / Apoe / mice at
4 weeks post HFCD or in mice that were on chow diet only
(Supplementary Fig. 1a–d). Moreover, in contrast to the
signiﬁcant impact of TREM-1 on the extent of atherosclerotic
surface area in the aorta at 16 weeks post HFCD, this effect was
not revealed by the analysis of the cross-sectional lesion area at
the aortic root. We propose that the most likely explanation for
this seeming discrepancy is in fact the mechanism by which
TREM-1 inﬂuences atherogenesis. In particular, by exacerbating
HFCD-induced monocytosis TREM-1 will likely enhance the
progression of already established lesions. Since lesions at the
aortic root are usually the ﬁrst to develop and represent the most
advanced lesions throughout the aortic tree, at 16 weeks post
HFCD these lesions might have been too advanced to still reﬂect
the effects of TREM-1 on lesion development.
Under homeostatic conditions and on an ApoE-sufﬁcient
(Apoeþ /þ ) background, deﬁciency in TREM-1 has no
appreciable impact on haematopoietic processes29,31. Here, we
conﬁrm and extend these data by showing that colony-forming
capacity and colony subtype differentiation were comparable
for Trem1þ /þ Apoe / versus Trem1 / Apoe / mice
under chow diet feeding. Strikingly, the aggravated monocytosis
in HFCD-fed Trem1þ /þ Apoe / mice was not related to an
increased expansion of haematopoietic stem or progenitor cells.
Instead, we found that HFCD-feeding of Trem1þ /þApoe /
mice signiﬁcantly skewed myeloid differentiation in lin BM
cells towards increased monocyte production. Since GMP express
distinct levels of surface TREM-1 (Supplementary Fig. 2c)31, this
suggested a potential cell-autonomous fashion by which TREM-1
could regulate monocytic over granulocytic lineage speciﬁcation.
However, unlike what was observed for peripheral blood myeloid
cells, HFCD feeding did not further increase surface TREM-1
expression on GMP (Supplementary Fig. 2c). Moreover, although
ex vivo isolated GMP from Trem1þ /þ Apoe / mice exhibited
increased mRNA levels for Irf8, a key transcription factor for
monocytic lineage differentiation42, stimulation of these GMP
with plate-bound anti-TREM-1 in the presence or absence
of HFCD serum was not sufﬁcient to augment monocyte
differentiation in vitro (Supplementary Fig. 2d,e). Whereas
TREM-1 has been demonstrated a potent ampliﬁer of cytokines
such as M-CSF, GM-CSF, IL-6 and CCL2 (ref. 56), expression
levels of these cytokines in the serum or bone ﬂushes from
HFCD-fed Trem1þ /þ Apoe / mice were generally close to the
detection limit (Supplementary Fig. 6a,b). Hence, the question
whether the HFCD-induced effect of TREM-1 on monopoiesis
may be cell-intrinsic or extrinsic could not be conclusively
addressed within the scope of the present study. Clearly, the
complex contribution of TREM-1 to monopoiesis needs to be
deciphered in further investigations that can take into account the
multifarious dyslipidemia-induced changes in dietary PAMPs and
cytokines in vivo.
While our ﬁndings show that TREM-1 can contribute to
atherosclerosis through regulation of the BM and peripheral
monocyte pool, resulting in increased monocyte/macrophage
accumulation and lesion progression, our data also suggest that
TREM-1 may promote atherosclerotic lesion progression in situ.
In parallel with the increased abundance of monocyte/macro-
phage foam cell-associated transcripts, expression of Trem1 was
highly upregulated in the aortic arch of 16 week HFCD-fed
Trem1þ /þ Apoe / mice. TREM-1 surface expression on
lesion-inﬁltrating cells could further be conﬁrmed by ﬂow
cytometry. Moreover, major differences in the composition of
CD11bþ cells in digested aortas of Trem1þ /þ Apoe / versus
Trem1 / Apoe / mice could be attributed to Ly6C
macrophages but not to Ly6Chi monocytes or neutrophils,
arguing against a primary defect in monocyte recruitment in
Trem1 / Apoe / mice.
The presence of two distinct Ly6C CD64þ MHCIIþ versus
Ly6C CD64þ MHCII aortic macrophage populations is
intriguing, in particular, as MHCII , but not MHCIIþ ,
macrophages expressed TREM-1 and were more abundant in
aortas of Trem1þ /þ Apoe / mice. To date, relatively few
studies have performed detailed ﬂow cytometry characterizations
of aortic macrophage subsets. The existence of CD11bþ F4/80þ
MHCIIlo macrophages has been described for the steady-state
aorta44 and for the heart where multiple embryonic and adult
macrophage subsets have been identiﬁed with different signatures
for MHCIIhi versus MHCIIlo macrophages57. A recent study has
suggested a similarly complex picture and multilayered origin
for resident arterial macrophages12. As under homeostatic
conditions, arterial macrophage populations appear to be
sustained largely by self-renewal12, yet recruitment of Ly6Chi
monocytes is critically associated with foam cell formation in
atherosclerosis2,3,8,9, it is difﬁcult to link the MHCIIþ and
MHCII macrophage populations identiﬁed in our study with
the macrophage subsets described by Ensan et al.12. Our attempts
to further characterize aortic macrophages in Trem1þ /þ Apoe /
versus Trem1 / Apoe / mice were hampered by the very
low cell yield, which precluded robust gene expression analysis in
sorted cell subsets. Hence, we can currently only speculate
about the origin and functional proﬁle of the aortic MHCII
TREM-1þ versus MHCIIþ TREM-1 macrophages. Based on
ﬁndings from experimental colitis models, where the expression
pattern of TREM-1 has already been characterized, TREM-1 is
expressed by inﬁltrating Ly6Chi effector monocytes and their
Ly6Clo descendants but not by resident Ly6C MHCIIþ
macrophages in the inﬂamed colon47. Moreover, during
intestinal inﬂammation, regular differentiation of Ly6Chi
monocytes to Ly6C MHCIIþ macrophages is arrested at
the intermediary stage of Ly6Cint MHCIIþ macrophages with
pro-inﬂammatory properties45–47. In aortas of HFCD-fed
Trem1þ /þ Apoe / mice, highest TREM-1 MFI values
among inﬁltrating Ly6G CD11bþ cells were observed in
Ly6Cint MHCIIþ macrophages. While it remains to be
determined whether Ly6Cint MHCIIþ cells give rise to Ly6C
MHCII TREM-1þ macrophages in vivo, our preliminary data
indicate a distinct down-modulation of HLA-DR after
differentiation of human monocytes in the presence of M-CSF
and agonistic anti-TREM-1 stimulation in vitro (Supplementary
Fig. 7a,b). At least an initial Ly6Chi monocytic origin of Ly6Cint
MHCIIþ TREM-1þ macrophages appears conceivable also for
the aorta2,3,8. In mice with experimental colitis, TREM-1 is barely
expressed on peripheral blood Ly6Chi monocytes47, and although
in HFCD-fed Trem1þ /þ Apoe / mice TREM-1 expression
was upregulated on all peripheral blood cell subsets, TREM-1
surface expression on Ly6Chi monocytes remained low. Hence,
TREM-1 must become upregulated on inﬁltrating monocytes
following transmigration to inﬂamed tissues. Whereas in the
colitic intestinal mucosa, TREM-1 is likely induced by microbial
factors27,58,59, in the subendothelial space of aortic vessels a role
for non-microbial DAMPs appears more probable as we observed
potent upregulation of TREM-1 under dyslipidemic conditions
in vivo and upon stimulation of primary monocytes with HFCD
serum or puriﬁed oxLDL in vitro. Besides oxLDL or dietary
DAMPs also GM-CSF secreted by endothelial cells could mediate
local induction of TREM-1 (refs 15,43).
The factors that may engage and activate TREM-1 in aortic
lesions are more difﬁcult to grasp, in particular, as TREM-1
ligands remain incompletely deﬁned. In contrast to other TREM
family members, TREM-1 does not appear to participate in
recognition of lipids60,61. Nonetheless, the recently described
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capacity of the PAMP molecule HMGB1 (refs 28,29) and
multimerized PGLYRP1 (ref. 30) to associate with and
stimulate TREM-1 provides a possible scenario for activation of
lesion-associated myeloid cells in the context of non-infectious
inﬂammation. PGLYRP1 is expressed by neutrophils which seem
abundant enough in murine lesions. Moreover, HMGB1 is
released from macrophage foam cells that accumulate in
advanced atheromas18,19. An HMGB1-mediated local triggering
of TREM-1 in concert with the progressive monocytosis in
Trem1þ /þ Apoe / mice could provide an explanation for the
impact of TREM-1 on lateral lesion growth rather than early
lesion initiation. It is also tempting to speculate that TREM-1,
possibly in association with other receptors such as RAGE, may
be involved in the recently reported priming of lesional
macrophages by neutrophil extracellular traps62.
A striking ﬁnding of the present study was the potent effect of
TREM-1 on foam cell formation in vitro. Although innate
immune signalling pathways have previously been acknowledged
to antagonize compensatory cholesterol efﬂux mechanisms63,
the direct impact of TREM-1 on foam cell conversion was
unanticipated, considering that TREM-1 on its own otherwise has
poor stimulatory capacity25. TREM-1-mediated stimulation of
U937-TD cells but also of primary human monocytes associated
with a pronounced upregulation of the oxLDL scavenger receptor
CD36. The TREM-1-induced expression of CD36 is consistent
with the augmented expression of PPARg as a TREM-1-regulated
gene56 and the role of PPARg as key regulator of CD36
expression and foam cell formation64,65. It is further
noteworthy that in the converse expression of molecules on
mouse and human monocyte subsets TREM-1 segregates with
PPARg and CD36 and that both TREM-1 and CD36 are
upregulated during steady-state differentiation of Ly6Chi to
Ly6Clo monocytes66,67. Moreover, CD36 has been ascribed a
central role in facilitating TLR4/6 assembly leading to increased
pro-inﬂammatory cytokine and ROS production24. Notably, in
primary human monocytes TREM-1 not only augmented mRNA
expression of PPARG and CD36 but also of other receptors
implicated in lipid uptake such as MSR1 and LDLR. Whether the
clear impact of TREM-1 on several other genes involved in
intracellular cholesterol metabolism represents a direct effect of
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Figure 8 | Model for multilayered pathogenic roles of TREM-1 in diet-induced atherogenesis. (1) TREM-1 skews myeloid differentiation towards
increased monocyte output by yet undetermined direct or indirect mechanisms, likely acting together with microbial or dietary PAMPs which become
systemically available following HFCD feeding. (2) These factors may also be involved on the upregulation of TREM-1 on peripheral blood myeloid cell
subsets. (3) TREM-1 is further upregulated on Ly6Chi monocytes following their transmigration to the intima and exposure to oxLDL. (4) Activation of
monocytes via TREM-1 may be mediated by neutrophil-derived PGLYRP1 (not depicted) or by HMGB1 released by activated or necrotic macrophages.
(5) TREM-1-mediated activation promotes the expression of scavenger receptors CD36, MSR1 and the LDLR and thereby increases lipid uptake. TREM-1
further promotes foam cell formation by interfering with intracellular cholesterol transport and efﬂux mechanisms (not depicted). (6) CD36 facilitates
TLR4/6 assembly and NLRP3 activation (not depicted) leading to increased pro-inﬂammatory cytokine and ROS production, which may contribute to
additional lipid peroxidation. Concurring TREM-1-mediated activation could further amplify these pro-inﬂammatory processes. (7) Increased uptake of
oxLDL leads to the differentiation of Ly6Chi monocytes to Ly6C macrophage foam cells through a Ly6Cint TREM-1þ MHCIIþ intermediary stage.
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TREM-1 or compensatory response to the increased lipid content
remains to be determined.
In support of our hypothesis that TREM-1 may promote
atherosclerotic lesion progression locally, we found highly
upregulated expression of mRNA for TREM-1 also in human
aortic tissue specimens displaying severe atherosclerosis. Thus,
it is tempting to speculate that the proposed association of
distinct TREM1 polymorphisms with coronary artery disease in a
Russian population may be causal54. In the Swiss population-
based CoLaus study68, an association of the TREM1 single-
nucleotide polymorphism (SNP) rs2234237 with self-reported
cardiovascular disease could not be established. Nonetheless, in a
substudy of CoLaus, participants with the TT genotype had
signiﬁcantly lower intima-media thickness (IMT) maximal values
for the left carotid artery compared with AA or AT genotype
carriers, with a signiﬁcant additive effect (Po0.006 for trend);
a similar, albeit non-signiﬁcant, trend was found for the right
carotid artery (Supplementary Table 3). Therefore, the potential
signiﬁcance of TREM-1 for human cardiovascular disease clearly
merits more attention.
In summary, while the precise mechanisms behind TREM-1-
mediated lesion progression remain to be further determined, we
propose a multiphasic model for TREM-1 in atherogenesis
(Fig. 8): In the periphery, TREM-1-mediated signalling
skews myelopoiesis towards increased production of monocytes.
In atherosclerotic lesions, TREM-1 participates in a positive
feedback-loop with oxLDL and CD36, thus contributing to
increased lipid uptake and foam cell formation. This process may
additionally be boosted by multiple adverse effects of TREM-1 on
cellular lipid uptake, transport and efﬂux mechanisms as well as
by TREM-1-ampliﬁed lipid peroxidation and pro-inﬂammatory
cytokine production in concert with TLR4/6. Our ﬁndings thus
identify TREM-1 as a key innate immune receptor participating
in the chronic inﬂammatory process in atherosclerosis.
Methods
Mice. Trem1 / mice (C57BL/6) were generated and characterized in our
laboratory31. Apoe / (B6.129P2-Apoetm1Unc/J) mice (C57BL/6), were purchased
from Charles River Laboratories (USA). Trem1 / mice were backcrossed with
Apoe / mice to generate Trem1þ /þ Apoe / and Trem1 / Apoe / mice.
Mice were maintained in isolated ventilated cages under speciﬁc pathogen-free
conditions. Fourteen days before and every 14 days throughout feeding
experiments, bedding between Trem1þ /þ Apoe / and Trem1 / Apoe /
mice was exchanged to adjust for potential differences in microbiota composition.
All experimental procedures were approved by the Veterinary Ofﬁce of the Canton
of Bern (license no: 111/14) and performed in compliance with Swiss laws for
animal protection.
Induction of experimental atherosclerosis. Six- to eight-week-old female
Trem1þ /þ Apoe / and Trem1 / Apoe / mice were either further
maintained on a regular chow diet or placed on a high-fat, high cholesterol diet
(HFCD) (D12007C, Research Diet Inc., New Brunswick, NJ USA) for 4-16 weeks
as indicated.
Determination of atherosclerotic lesion size. Following euthanasia by
CO2-exposure, mice were perfused for 5min with ice-cold PBS and subsequently
with 4% buffered paraformaldehyde (PFA) containing 2mM EDTA and 2%
glucose. Whole aortas including the initial parts of the brachiocephalic artery, the
left common carotid artery, the left subclavian artery the right and left iliac arteries
were carefully freed from all connective tissue and fat, were cut open longitudinally
and pinned ‘en face’ on petri dishes coated with activated carbon blackened
parafﬁn. Atherosclerotic lesions were visualized by staining in 0.3% Oil-Red-O
(Sigma, Switzerland) staining solution in 60% isopropanol. The aortic surfaces were
photographed (D90, Nikon) and the lesion sizes were measured using ImageJ
software (version 2.0.0-rc-43/1.51c). The extent of atherosclerosis was determined
by calculating the ratio of the lesion-covered surface area compared to the total
surface area of the aorta.
To analyse cross-sections of the aortic root, hearts were cut in half and the
upper part was embedded in O.C.T. (TissueTek, Sakura Finetek Europe,
Leiden, NL). Cross-sections (6 mm thick) were prepared from the frozen hearts on a
Leica CM1950 cryostat (Leica Biosystems Germany). Ten cross-sections of the
aortic root were collected every 36 mm, stained with ORO and counterstained with
Mayer’s hematoxylin staining solution. Sections were analysed on a Zeiss Axiophot
2 (Zeiss, Germany) and the lesion area was calculated using ImageJ software in a
blinded manner.
Analysis of serum lipid and soluble TREM-1 (sTREM-1). Serum was obtained
from whole blood collected from the ‘vena cava’ of o/n fasted mice. Total
cholesterol, HDL and LDL cholesterol were determined by the Department of
Clinical Chemistry of the University of Bern on a cobas 8000 clinical chemistry
analyser (Roche diagnostics, Switzerland). sTREM-1 was determined by ELISA
(R&D Systems, USA).
Nanostring gene expression proﬁling of aortic RNA. Aortas were prepared
as described above but without PFA perfusion. Aortas were cut in four pieces
consisting of the aortic arch, descending thoracic aorta, abdominal aorta and
the iliac bifurcation and stored in RNAlater (Life Technologies, USA). For
RNA isolation, aortic pieces were transferred into TRI Reagent (Sigma-Aldrich,
Switzerland) and tissues were homogenized with a Qiashredder (Qiagen) 2 at
20Hz for 5min. RNA was then isolated according to the manufacturer’s protocol.
For mRNA expression proﬁling, the nCounter Mouse Immunology panel
(Nanostring technologies, Seattle, USA) was complemented with additional 30
genes of interest (Supplementary Table 1). Expression levels of mRNA for TREM-1
and other TREM family members were veriﬁed by SYBR-green (Roche,
Switzerland) based qRT-PCR analysis using QuantiTect primer assays (Qiagen)
and normalization to Gapdh (Mm_Gapdh, QT01658692; Mm_Trem1,
QT00153979; Mm_Cd68, QT00254051; Mm_Ly6g, QT00529655).
Isolation of cells from murine tissues. Peripheral blood was collected from the
‘vena cava’ post mortem or from the lateral tail vein from live animals during
HFCD feeding. Single-cell suspensions from spleen were prepared by the enzymatic
digestion protocol used for aortic cell preparation as described below. For BM cells,
tibiae and femurs were placed in RPMI 1640 medium supplemented with 10% FCS
and ﬂushed with a 26 GA 3/8 needle. Peripheral blood, spleen and BM cells were
erythrocyte-depleted with Tris-buffered ammonium chloride. For preparation
of aortic single-cell suspensions, aortas were carefully dissected and freed from
connective tissue. Aortas were incubated in HEPES-buffered saline containing 5%
horse serum as well as collagenase I (1,350Uml 1, Sigma), Collagenase XI
(375Uml 1, Sigma), Hyaluronidase type I-s (180Uml 1, Sigma) and DNase I
(180Uml 1, Roche) for 100min at 37 C with magnetic stirring. Digested aortas
were ﬁltered through 45 mM cell strainers (Falcon Technologies, BD) to obtain
single-cell suspensions.
Flow cytometry characterization of murine cell subsets. Peripheral blood
and aortic single-cell suspensions were Fc-blocked and stained with
the following monoclonal antibodies (mAbs) (Biolegend, San Diego, USA,
unless indicated otherwise): anti-CD45-Paciﬁc Blue (30-F11; 0.25 mgml 1),
anti-CD11b-PE-Cy7 (M1/70; 0.5 mgml 1), anti-MHC class II-APC-Cy7
(M5/114.15.2; 0.067 mgml 1), anti-CD11c-Alexa Fluor 700 (N418; 2.5 mgml 1),
anti-Ly6C-FITC (AL-21; 0.5 mgml 1), anti-F4/80-PE-Cy7 (BM8, 0.5 mgml 1)
(BD Pharmingen, USA), anti-Ly6G-PerCP-Cy5.5 (1A8; 0.2 mgml 1), anti-CD64-
PE (X54-5/7.1; 2 mgml 1), anti-TREM-1-eFluor 660 (TR3MBL1; 0.2 mgml 1)
(eBioscience, USA). Following matched ﬂuorochrome labelled isotype control
antibodies were included: for CD11c: armenian hamster Ig (HTK888); for CD64:
mouse IgG1(MOPC-21) (BD Pharmingen); for TREM-1: rat IgG2a (eBR2a)
(eBioscience). BM cells were lineage-depleted with MACS (Miltenyi Biotech)
using anti-CD19-biotin (6D5; 1.67 mgml 1), anti-CD3e-biotin (145-2C11;
1.67 mgml 1), anti-Gr1-biotin (RB6-8C5; 1.67 mgml 1) anti-Ter119 (Ter119;
1.67 mgml 1) (Biolegend) and anti-biotin Microbeads (Miltenyi Biotec).
Lineage-depleted cells were stained for HSC and myeloid progenitors with
anti-CD127-PE (SB/199; 2 mgml 1), anti-CD117-APC-Cy7 (2B8; 0.67 mgml 1),
anti-CD16/32-PE-Cy7 (93; 0.5 mgml 1) (Biolegend) and anti-Ly-6A/E
(Sca-1)-PerCP-Cy5.5 (D7; 0.33 mgml 1), anti-CD34-eFluor450 (RAM34;
2 mgml 1) (eBioscience). For all cell acquisitions, live-dead exclusion was
performed using DAPI (Sigma; 0.5 mgml 1) or LIVE/DEAD ﬁxable blue dead
cell stain kit (Thermo Fisher Scientiﬁc, USA). Cells were acquired on a LSRII
(BD Biosciences, USA) and ﬂow cytometry data were analysed using FlowJo
version 9.9 or version 10.1 .
Myeloid colony-forming unit assays. A total of 5 103 lin BM cells were
cultured in MethoCult base medium (STEMCELL Technologies, Grenoble, France)
supplemented with 15% FCS, 20% BIT (50mgml 1 BSA in Iscove’s modiﬁed
Dulbecco’s medium, 1.44Uml 1 rh-insulin (Actrapid, Novo Nordisk, Denmark),
and 250 ngml 1 human Holo Transferrin [ProSpec, USA]), 100mM
2-b-mercaptoethanol, 100Uml 1 penicillin, 100 mgml 1 streptomycin,
2mM L-glutamine, and a cytokine mix of 50 ngml 1 rm-SCF, 10 ngml 1
rm-IL-3, 10 ngml 1 rh-IL-6, and 50 ngml 1 rm-Flt3-ligand (all from ProSpec,
USA). Colonies were enumerated after 7 days of culture. Colony subtypes were
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determined by inverted light microscopy and by Pappenheim staining of
individually plucked colonies.
Analysis of human peripheral blood CD14hi monocytes. Buffy coats were
obtained from the local blood donation center. PBMCs were puriﬁed by
Ficoll-Paque PLUS gradient centrifugation (GE Healthcare, UK) and stained for
FACS puriﬁcation with anti-human CD14-Alexa Fluor 488 (HCD14; 0.4 mgml 1)
and CD16-Paciﬁc Blue (3G8; 0.1 mgml 1) (Biolegend). Sorted CD14hi monocytes
were cultured at 100,000 cells per well in 96-well U-bottom plates pre-coated with
10mgml 1 agonistic anti-TREM-1 antibody (MAB1278) (R&D Systems) or an
isoype control antibody (MOPC21) (Biolegend). Where indicated, the culture
medium (RPMI 1640 with 10% FCS) was supplemented with either 30 ngml 1
LPS (Sigma), 50mgml 1 endotoxin-free oxLDL (Biomedical Technologies, Italy)
or with 5% heat-inactivated murine serum from 16-week HFCD-fed Trem1þ /þ
Apoe / mice. Following 20 h in vitro culture, supernatants were harvested
and used for TNFa, IL-1a and IL-1b ELISAs (Biolegend) according to the
manufacturer’s protocols. In some experiments, monocytes were harvested into
TRI Reagent for RNA isolation and qRT-PCR of cholesterol-metabolism associated
genes using QuantiTect primer assays (Qiagen). (Hs_CD36: QT00020181,
Hs_MSR1: QT00064141, Hs_LDLR: QT00045864, Hs_ABCA1: QT00064869,
Hs_ABCG1: QT00021035, Hs_PPRG: QT00029841, Hs_NPC1: QT00066465,
Hs_NPC2: QT00064904, Hs_STARD4: QT00015925, Hs_LIPA: QT00021679,
Hs_GAPDH: QT00079247). For ﬂow cytometry, monocytes were detached by
incubation with Accutase (Innovative Cell Technologies, USA) and stained
with anti-human TREM-1-APC (TREM-26; 0.25 mgml 1) or a matched isotype
control antibody (MOPC-173) (Biolegend). Foam cell formation capacity
of human monocytes was analysed after 48 h of culture as described below for
U937-TD cells.
Culture of U937-TD cells and foam cell formation in vitro. U937
myelomonocytic cells stably transduced with human TREM-1 and DAP12
(U937-TD) were generated by Tessarz et al.53. U937-TD cells were cultured in
RPMI 1640 supplemented with 10% FCS. For foam cell formation assays and
analysis of CD36 surface expression, U937-TD cells were cultured at 75,000
cells per well in 96-well U-bottom plates pre-coated with 10 mgml 1 agonistic
anti-TREM-1 antibody (MAB1278) or an isotype control antibody (MOPC21) in
the presence or absence of 30 ngml 1 LPS (Sigma) or 5% heat-inactivated serum
obtained from 16-week HFCD-fed Trem1þ /þ Apoe / mice. After 48 h of
culture, cells were gently detached by Accutase (Innovative Cell Technologies) and
stained with anti-human CD36-APC (5–271; 0.125 mgml 1) (Biolegend) for ﬂow
cytometry. Alternatively, 100,000 cells per 100ml were cytospun for 1min at
800 r.p.m. onto Superfrost Plus microscope slides (Thermo Scientiﬁc). After
ﬁxation in 4% PFA in PBS, slides were stained with 0.3% Oil-Red-O staining
solution in 60% isopropanol for 30min, washed with PBS and counterstained with
DAPI (Sigma; 0.5 mgml 1). Images were acquired on a Olympus IX81 confocal
microscope at 200 magniﬁcation. The ratio ORO:DAPI was assessed by
calculating the respective total pixels with ImageJ software.
Human aortic tissue specimens. Human FFPE aortic tissue specimens were
collected at the Institute of Pathology, University of Bern between 2011–2013 with
the written consent of patients and the approval by the Ethics Committee Bern,
Switzerland. Suitable specimens were selected by an expert pathologist (Y.B.) and
based on histological criteria from the analysis of H&E stained tissue sections
categorized into either specimens with minor alterations or with severe
atherosclerotic plaques. RNA from ﬁve 10 mm thick FFPE tissue roles was
puriﬁed using a column-based approach described by Oberli et al.69. SYBR-green
(Roche) based qRT-PCR was performed using QuantiTect primer assays
(Qiagen) (Hs_TREM1: QT00046284, Hs_CD68: QT00037184, Hs_FUT4(CD15):
QT00223657).
CoLaus substudy and intima-media thickness (IMT) measurements. Clinical
characteristics of the CoLaus68 substudy participants according to the TREM1 SNP
rs2234237 genotype are provided in Supplementary Table 4. IMT was assessed
using B-mode high resolution imaging of the carotid arteries. IMT values are
expressed in mm.
Statistical analyses. All data except for Nanostring data and IMT data were
analysed using Prism software version 5.0f. Statistical tests were used as indicated
in the ﬁgure legends. In general, the two-tailed Mann–Whitney t-test was
performed to compare two groups. One-way analysis of variance (ANOVA) test
with Dunn’s multiple comparison test was used to compare three or more groups
with each other. Two-way ANOVA test with Bonferroni correction was used to
compare multiple data groups with two independent variables. For analysis of the
Nanostring data, signiﬁcant differences in gene expression were calculated between
the wild-type and knock-out groups of each age-diet group. Gene expression values
were ﬁrst log-transformed. The Bioconductor limma package was used to perform
a moderated t-test on all genes70. Principal component analysis was done in R and
the results were visualized with the ggplot2 package71.
For IMT, between-group comparisons were performed using one-way ANOVA
and the results were expressed as mean±s.d. Multivariable analysis was performed
using ANOVA adjusting for gender, smoking status (never, former, current),
age (continuous) and body mass index (continuous) and the results were expressed
as adjusted mean±s.e. Genetic effect was assessed supposing an additive effect and
applying the qtlsnp procedure of Stata. Statistical analysis was conducted using
Stata version 13.1 (Stata Corp).
Study approval. Patients and blood donors gave written informed consent.
Analyses of human formalin-ﬁxed parafﬁn-embedded tissue specimens was
approved by the Ethics Committee Bern, Switzerland.
Data availability. All relevant data that support the ﬁndings of this study,
including the full Nanostring gene expression proﬁling data, are available from the
corresponding authors on request.
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